CXCL12 Eluting Matrix for Immune Rejection Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for transplanting cells to treat autoimmune disorders like type I diabetes are limited by acute and chronic immune rejection, which are managed with continuous systemic immune suppression, leading to increased risks of infection and cancer, and require long-term immunosuppression.

Innovation Solution

A CXCL12 polypeptide eluting matrix is used to encapsulate cells, repelling effector T-cells and recruiting immune-suppressive regulatory T-cells, thereby overcoming the need for systemic immune suppression by providing site-specific immune modulation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If continuous systemic immune suppression is used to manage immune rejection, then immune rejection is suppressed, but the risk of infection and cancer increases

Engineering Contradiction:

Improveimmune rejection suppressionVSAvoidinfection and cancer risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by delivering CXCL12 polypeptide specifically to the transplant site through an eluting matrix, creating a localized immunomodulatory environment. This local delivery approach concentrates the immune-modulating effect at the graft site without requiring systemic immunosuppression, thereby suppressing immune rejection locally while avoiding the widespread immunosuppression that causes infection and cancer risks

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The CXCL12 polypeptide acts as an intermediary molecule that mediates immune modulation at the transplant site. The eluting matrix serves as a delivery intermediary that releases CXCL12 in a controlled manner. This intermediary approach replaces the need for direct systemic immunosuppression with a targeted local immune-modulating mechanism, reducing harmful side effects

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If cell transplantation is performed to treat autoimmune disorders, then curative potential is achieved, but acute and chronic immune rejection occurs

Engineering Contradiction:

Improvecurative effectivenessVSAvoidtransplant survival time

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent applies preliminary action by pre-loading the matrix with CXCL12 polypeptide before cell transplantation. This pre-prepared matrix is ready to immediately release CXCL12 upon implantation, creating a protective immunomodulatory environment around the transplanted cells from the outset. This preliminary preparation ensures that immune rejection is countered before it can severely damage the graft, extending transplant survival

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The CXCL12 polypeptide eluting matrix serves as an intermediary protective layer between the transplanted cells and the host immune system. It mediates the interaction by releasing CXCL12 that modulates immune cell behavior, protecting the transplanted cells from acute and chronic rejection while maintaining their therapeutic function over extended periods

Inventive Principle:

Principle #24Intermediary (Mediator)

3Duration of action of stationary object

If systemic immune suppression is used long-term, then immune rejection is controlled, but side effects accumulate

Engineering Contradiction:

Improveimmune rejection control durationVSAvoidimmunosuppression side effects

Core Design Contradiction:

Duration of action of stationary objectVSObject-generated harmful factors

Solution Approach 1:

The patent extracts the immune modulation function from the systemic circulation and concentrates it locally at the transplant site through the eluting matrix. By taking out the need for systemic immunosuppression and replacing it with localized CXCL12 delivery, the invention maintains long-term immune rejection control duration while eliminating the accumulated side effects of systemic immunosuppressive medications

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention implements local quality by creating a site-specific immunomodulatory environment using the CXCL12-eluting matrix. This localized approach provides sustained immune rejection control at the transplant site without the need for long-term systemic immunosuppression, thereby maintaining duration of protection while avoiding the harmful side effects that accumulate with prolonged systemic medication use

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The CXCL12 polypeptide eluting matrix effectively delays or prevents immune destruction of implanted cells, allowing for prolonged survival and function of transplanted islets without the need for systemic immunosuppression, maintaining blood glucose levels within a normal range for extended periods.

Implementation Method 1

CXCL12 polypeptides can repel effector T-cells while recruiting immune-suppressive regulatory T-cells to an anatomic site

Methodology Applied

Scientific EffectChemotaxis:

Implementation Method 2

The CXCL12 polypeptide eluting matrix is characterized by a release of the CXCL12 polypeptide at a rate sufficient to repel effector T cells

Methodology Applied

Scientific EffectElution:

Data Source

PatentEP3065701B1Eluting matrix and uses thereof

Publication Date: 2021.01.06 THE GENERAL HOSPITAL CORP

Figure 1A~1B
Figure 1C~1D
Figure 2A~2B

AI summary

CXCL12 polypeptide eluting matrices encapsulating at least one cell are described for use in the treatment of autoimmune disorders.